

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The Immunology of Thymectomy And childhood Cardiac transplant (ITHACA): Protocol for a prospective nationwide cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-079582
Article Type:	Protocol
Date Submitted by the Author:	05-Sep-2023
Complete List of Authors:	<p>Offor, Ugonna; Newcastle University Faculty of Medical Sciences, Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute.; Great North Children's Hospital, Department of Paediatric Haematology and Oncology</p> <p>Hollis, Paolo; Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Cardiothoracic Transplant</p> <p>Ognjanovic, Milos; Great North Children's Hospital, Department of Paediatric Nephrology</p> <p>Parry, Gareth; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Cardiopulmonary Transplantation</p> <p>Khushnood, Abbas; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Cardiopulmonary Transplantation</p> <p>Long, Heather; University of Birmingham, Institute of Immunology and Immunotherapy</p> <p>Gennery, Andrew; Newcastle University Faculty of Medical Sciences, Translational and Clinical Research Institute; Great North Children's Hospital, Department of Paediatric Immunology and Haematopoietic Stem Cell Transplantation</p> <p>Bacon, Chris; Newcastle University Faculty of Medical Sciences, Wolfson Childhood Cancer Research Centre, Translational Research and Clinical Research Institute.; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Cellular Pathology</p> <p>Simmonds, Jacob; Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Cardiothoracic Transplant</p> <p>Reinhardt, Zdenka; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Cardiopulmonary Transplantation</p> <p>Bomken, Simon; Newcastle University Faculty of Medical Sciences, Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute.; Great North Children's Hospital, Department of Paediatric Haematology and Oncology</p>
Keywords:	Paediatric transplant surgery < PAEDIATRIC SURGERY, Paediatric oncology < ONCOLOGY, Lymphoma < ONCOLOGY, IMMUNOLOGY, Risk Factors, Observational Study

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **The Immunology of Thymectomy And childhood CARDiac transplant (ITHACA): Protocol for**
4 **a prospective nationwide cohort study to identify immunological risk factors of post-**
5 **transplant lymphoproliferative disease (PTLD) in thymectomised children.**
6
7

8 Ugonna T Offor^{1,2}; Paolo Hollis³; Milos Ognjanovic⁴; Gareth Parry⁵; Abbas Khushnood⁵;
9 Heather M Long⁶; Andrew R Gennery^{7,8}; Chris M Bacon^{1,9}; Jacob Simmonds³; Zdenka
10 Reinhardt⁵; Simon Bomken^{1,2}.
11
12
13
14
15

16 ¹Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute,
17 Newcastle University, Newcastle upon Tyne, United Kingdom.
18

19 ²Department of Paediatric Haematology and Oncology, The Great North Children's Hospital,
20 Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United
21 Kingdom.
22
23
24

25 ³Department of Cardiothoracic Transplant, Great Ormond Street Hospital for Children NHS
26 Foundation Trust, London, United Kingdom.
27
28

29 ⁴ Department of Paediatric Nephrology, Great North Children's Hospital, Newcastle upon
30 Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
31

32 ⁵Department of Cardiopulmonary Transplantation, Newcastle upon Tyne Hospitals NHS
33 Foundation Trust, Newcastle upon Tyne, United Kingdom.
34
35

36 ⁶Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
37

38 ⁷Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne,
39 United Kingdom.
40

41 ⁸Department of Paediatric Immunology and Haematopoietic Stem Cell Transplantation, The
42 Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust,
43 Newcastle upon Tyne, United Kingdom.
44
45
46

47 ⁹Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust,
48 Newcastle upon Tyne, United Kingdom.
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction:

Paediatric heart transplant patients are disproportionately affected by Epstein-Barr virus-related posttransplant lymphoproliferative disease (EBV-PTLD) compared to other childhood solid organ recipients. The drivers for this disparity remain poorly understood. A potential risk factor within this cohort is the routine surgical removal of the thymus – a gland critical for the normal development of T-lymphocyte mediated antiviral immunity – in early life, which does not occur in other solid organ transplant recipients. Our study aims to describe the key immunological differences associated with early thymectomy, its impact on the temporal immune response to EBV infection and subsequent risk of PTLD.

Methods and analysis:

Prospective and sequential immune monitoring will be performed for 34 heart transplant recipients and 6 renal transplant patients (aged 0-18 years), stratified into early (<1-year), late (>1-year) and non-thymectomy groups. Peripheral blood samples and clinical data will be taken before transplant and at 3-, 6-, 12- and 24-months post-transplant. Single cell analysis of circulating immune cells and enumeration of EBV-specific T-lymphocytes will be performed using high dimensional spectral flow cytometry with MHC I/II tetramer assay respectively. EBV antibodies and viral load will be monitored at each of the pre-defined study time points.

Ethics and dissemination:

Ethical approval for this study has been obtained from the North of Scotland Research Ethics Committee. The results will be disseminated through publications in peer-reviewed journals, presentations at scientific conferences and patient-centred forums, including social media.

Trial registration number: ISRCTN10096625

Strengths and limitations of this study

- This is the first prospective study to monitor the temporal immune response to EBV infection within a group of patients known to be at a high risk of developing PTLD.
- The integration of data from clinical parameters, in-depth immunophenotyping and EBV-specific T-lymphocyte functional assay permits robust analysis of potential predictive immune biomarkers.
- The multicentre study design optimises recruitment of participants.
- The primary study limitation is the low incidence of paediatric heart transplantation which may affect the rate of study recruitment.

Introduction

Post-Transplant Lymphoproliferative Disease (PTLD) is the most common childhood cancer in paediatric recipients of a solid organ transplant (SOT). This heterogeneous group of life-threatening lymphoid malignancies is typically driven by Epstein-Barr Virus (EBV) infection.^[1] PTLD comprises a histological spectrum that ranges from indolent non-destructive B-cell lymphoid infiltrates through to more aggressive and destructive polyclonal or monoclonal B-cell lymphomas e.g., Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These destructive PTLD subtypes are indistinguishable from high grade mature B-cell lymphomas seen in immunocompetent children.^[2] Their incidence is allograft-dependent and ranges from 1-2% in renal transplant recipients to as high as 10-15% in heart transplant patients.^[1,3]

PTLD has one of the worst clinical outcomes amongst childhood lymphomas. The estimated 2-year Event-Free Survival (EFS) is 70% compared to 94% in sporadic cases within the general paediatric population.^[4 - 6] In even starker contrast is the survival outcome for paediatric heart transplant patients, who ostensibly have an inferior EFS compared to other non-cardiac organ transplants.^[7, 8] The reasons for this potential disparity are still poorly understood, albeit partly ascribed to a higher incidence of therapeutic complications from organ rejection and treatment-related toxicities.^[9]

1
2
3 The pathogenesis of PTLD is complex and multifactorial. It involves the interplay between
4 EBV-driven lymphoproliferation, iatrogenic immunosuppression and the suspected functional
5 exhaustion of T-lymphocytes due to graft-initiated chronic antigen stimulation.^[10] The role of
6 EBV is clearly established in children, many of whom experience primary infection from an
7 EBV-mismatched organ. ^[1, 3, 4] In vitro and in vivo studies focused mainly on adult
8 monomorphic PTLD have demonstrated distinct patterns of viral protein expression in
9 infected B-lymphocytes. ^[10, 11] These expression patterns likely influence both the cellular
10 composition of the tumour immune microenvironment and aberrant immune signalling
11 which result in immune escape of tumour cells. ^[10]
12
13
14
15
16
17
18
19
20
21

22 In paediatric heart transplant patients, cardiac surgery via median sternotomy in early
23 childhood often requires routine thymectomy in order to access the heart and great vessels.
24 Our earlier study retrospectively examined risk factors for PTLD in the largest UK cohort of
25 paediatric orthotopic heart transplant (OHT) patients to date.^[3] The risk of PTLD was found to
26 be significantly higher in children with congenital heart disease (CHD) [Hazard Ratio = 3.2;
27 95% CI = 1.4–7.4] and early thymectomy in infancy [Hazard Ratio = 2.7; 95% CI = 1.3–5.2].^[3]
28 Furthermore, children with CHD had persistently lower T-lymphocyte counts compared to
29 children transplanted for acquired cardiomyopathy [CD4+: 430 cell/ μ l vs 963 cells/ μ l, $p < 0.01$
30 and CD8+: 367 cells/ μ l vs 765 cells/ μ l, $p < 0.01$].^[3] Similar studies have identified marked
31 phenotypic and functional disruptions to the T-lymphocyte compartment in paediatric heart
32 transplant patients compared to children receiving a liver or kidney transplant. ^[12, 13]
33
34
35
36
37
38
39
40
41
42
43

44 During the first year of life, the thymus plays a crucial role in the development of cell-
45 mediated immunity, providing a microenvironment for precursor T-lymphocytes to
46 proliferate and differentiate into mature (naïve) T-lymphocytes.^[14] Whilst it has been shown
47 that neonatal thymectomy alone is associated with premature immunosenescence and an
48 increased risk of viral infections such as Cytomegalovirus (CMV),^[14] little is known about the
49 immunological consequences of early thymectomy in immunosuppressed transplant
50 patients. In particular, there are no data on the synergetic impact of thymectomy and
51 transplant-related immunosuppression on EBV-specific immunity and the subsequent risk of
52 developing PTLD.
53
54
55
56
57
58
59
60

Study aims and hypothesis.

This study aims to investigate the development of EBV-specific immune responses following childhood heart transplant. Specifically, it aims to identify the impact of early thymectomy – compounded by iatrogenic immunosuppression – on EBV immunology and the risk of PTLD.

We hypothesise that a combination of early thymectomy and lifelong immunosuppression therapy establishes a tolerogenic immune profile consisting of dysregulated, exhausted and senescent immune cell subsets, poorly able to control EBV infection. This dysfunctional immune microenvironment permits the uncontrolled proliferation of EBV-infected B-lymphocytes and the subsequent development of PTLD.

Methods and analysis

Study design and setting

The Immunology of Thymectomy and Childhood Cardiac Transplant (ITHACA) study is a prospective nationwide cohort study recruiting children (0-18 years) from the two UK centres currently commissioned to provide paediatric heart transplant services: The Freeman Hospital, Newcastle upon Tyne and Great Ormond Street Hospital for Children, London. The study cohort will consist of 34 prospective heart transplant recipients and a non-thymectomy age-matched control group made up of 6 renal transplant recipients. All patients meeting the study's eligibility criteria will be identified and recruited through their local transplant teams at the time of listing for cardiac or renal transplantation.

Inclusion Criteria

- Aged 0 – 18 years.
- Actively listed on the NHS Blood and Transplant (NHSBT) waiting list for a primary organ transplant OR awaiting transplant with a living related donor kidney OR recently transplanted with pre-transplant blood samples available.
- Written informed consent.

Exclusion Criteria

- Has a pre-existing diagnosis of an inherited or acquired immunodeficiency.
- Has an underlying thymic disorder.
- Has previously received a bone marrow or organ transplant.
- Has had a previous cancer diagnosis.
- Withheld consent.
- Weight under 2.5kg.

Informed consent

Informed consent will be obtained from the parent/carer of the eligible child or from the patient themselves if over the age of 16 years. Assent may be given by children < 16 years of age who wish to do so.

A deferred consent approach will be employed for potential study participants who attend a research site's transplant service for transplantation in a critical/life threatening clinical situation. This will involve the collection of baseline study samples from potential participants at the point of pre-surgical workup without written informed consent being received. Discussion about the study, the giving of participant information sheet (PIS) and receiving of written informed consent/assent will be offered at a more appropriate time before further follow-up blood tests are taken. Such cases will require that the clinical team considers obtaining informed consent prior to transplant to be inappropriate. This will be documented in the patient's clinical notes. Study samples collected under such circumstances will be processed for storage but not analysed until written informed consent is obtained. Any patient who has study samples collected by deferred consent but subsequently declines enrolment in the study will have their samples destroyed in a timely manner according to local laboratory standard operating procedures (SOP). Additional consent will be sought to store specimens for future ethically approved research.

Assessment and procedures

1
2
3 Children will undergo blood sampling for study-specific investigations during routine clinical
4 visits prior to transplant and at 3-, 6-, 12- and 24-months post-transplant (Figure 1). No
5 additional study-related hospital visits are planned. Medical therapy will be applied as
6 clinically indicated and per the local post-transplantation protocols. A total of 5 – 20mls of
7 blood will be taken at each study time point for all participants. This will coincide with their
8 usual transplant-related investigations in adherence to WHO guidance for blood sampling in
9 child health research.^[15] In the case of a prolonged interval between the pre-transplant blood
10 sample and subsequent organ transplant (e.g., > 6 months) additional blood samples will be
11 specifically requested from the patient/parent and verbal consent recorded in the medical
12 record. Relevant clinical data will also be collected from participants at each study time point
13 (Supplementary Table 1).
14
15
16
17
18
19
20
21
22
23
24
25

26 Study investigations will consist of:

- 27 • Immunophenotyping of circulating immune cell subsets.
 - 28 • EBV serology.
 - 29 • EBV-specific T-lymphocyte quantification.
 - 30 • EBV-specific T-lymphocyte functional analysis.
- 31
32
33
34
35
36
37
38

39 Immunophenotyping of circulating immune cell subsets

40
41 Circulating immune cell populations will be analysed in Newcastle University laboratories.
42 Mononuclear cells (MNCs) will be isolated and cryopreserved from blood samples taken at
43 each study time point. Circulating immune cell subsets will be identified within samples using
44 high dimensional spectral flow cytometry (Aurora system [Cytex]). The 5-laser Aurora spectral
45 cytometer enables an in-depth analysis of up to 40 cell surface markers at a time.^[16] This is
46 highly valuable in phenotypically characterising various immune cell populations and their
47 subsets (including T-lymphocytes, B-lymphocytes, NK cells and dendritic cells) in low volume
48 paediatric samples.^[17] These samples will be analysed simultaneously in batches to mitigate
49 inter-assay variation. A comprehensive list of cell surface markers has been selected to
50 comprise the following:
51
52
53
54
55
56
57
58
59

- 60 (i) Major innate/adaptive cell lineages.

- 1
- 2
- 3
- 4 (ii) Main T-lymphocyte subsets as well as putative T-helper subsets.
- 5
- 6 (iii) Recent thymic activity.
- 7
- 8 (iv) Cellular exhaustion and senescence.
- 9
- 10 (v) Key innate/adaptive cells involved in immune response to EBV infection.
- 11
- 12
- 13

14 EBV serology

15
16 Routine blood samples for evaluation of EBV serology will be tested centrally in the Newcastle
17 upon Tyne NHS Hospitals Foundation Trust (NUTH) virology laboratories. EBV and CMV viral
18 load will be measured from whole blood using polymerase chain reaction (PCR) assays. Serum
19 and/or plasma will be tested for antibody response to key EBV proteins including IgM/IgG for
20 Viral Capsid Antigen (VCA) and IgG for EBV Nuclear Antigen 1 (EBNA-1). Results for viral load
21 assay will be reported as total titres while antibody testing will be reported as a binary
22 detected/not detected based on NUTH laboratories reference cut-off values.
23
24
25
26
27
28
29
30

31 EBV-specific T-lymphocyte quantification

32
33 An optimised panel of HLA-restricted peptide-MHC (pMHC) I/II tetramers will be used to
34 evaluate EBV-specific CD8 and CD4 T-lymphocyte immunity at the time points outlined in
35 Figure 1.^[18] Combinations of differently fluorescently labelled pMHC tetramers presenting
36 purified peptides of dominant lytic and latent EBV epitopes,^[19] relevant for the patient HLA
37 genotype, will be included in the T-lymphocyte panel. These customised tetramers will be
38 procured from the National Institute of Health (NIH) Tetramer Core Facility, Atlanta, Georgia,
39 USA.
40
41
42
43
44
45
46
47
48

49 EBV-specific T-lymphocyte functional analysis

50
51 To assess the functional capacity of EBV-specific T-lymphocytes in an HLA-unbiased manner,
52 effector cytokine production of interferon gamma (IFN- γ) will be determined by ELISpot
53 following stimulation with pools of overlapping peptides (JPT PepMix™) representing the full
54 sequences of a panel of EBV latent and lytic cycle proteins.^[20, 21]
55
56
57
58
59
60

Data collection

Study data will be collated and managed using Research Electronic Data Capture (REDCap) electronic case report forms (eCRF).^[22] REDCap is a secure, web-based platform specifically designed to support data acquisition for research studies. It provides restricted user rights to protect identifiable data, including audit trails for tracking data handling and export and procedures for data integration with external sources.^[23]

Outcome Measures

Primary Outcomes Measures:

- 1) Proportions of circulating innate and adaptive immune cell subsets before and at 3-, 6-, 12- and 24-months post-transplant.
- 2) Frequency of detectable EBV-specific T-lymphocyte immunity.
- 3) Functional capacity of EBV-specific T-lymphocytes.

Secondary Outcome Measures:

- 1) Incidence of EBV infection.
- 2) Time from transplantation to EBV viraemia.
- 3) Time from EBV viraemia to seroconversion.

Data analysis plan

Sample size calculation

As the study objectives are largely descriptive, no sample size calculation is necessary. Instead, we selected our sample size such that the study is feasible and large enough to conduct comprehensive analyses. Therefore, our sample size is based on a national average of 30 childhood cardiac transplants per year,^[24] and a 60% recruitment rate. All eligible patients listed on the National Health Service Blood and Transplant (NHSBT) register will be approached for consent, recognising that not all of these patients will receive a transplant during the lifetime of this study. However, any pre-transplant blood samples that have been obtained are equally important to achieve the study's primary outcome measure.

Statistical analysis

Data from spectral flow cytometry will be analysed using the OMIQ platform (<https://www.omiq.ai/>). Automated clustering and dimensionality reduction will be used to identify immune cell populations by FlowSOM and Uniform Manifold Approximation and Projection (UMAP) respectively. These techniques overcome the practical challenges associated with manual gating and user bias when analysing datasets from large flow panels. Statistically different immune signatures between patients with early thymectomy and late or non-thymectomy, EBV+ and EBV- serostatus, and between time-points, will be identified by linear and generalised linear mixed models (statistical significance defined as $p < 0.05$). Continuous variables will be assessed by Pearson correlation using the single linkage method to group patients by expression values, and non-continuous variables by non-parametric Spearman correlation, as appropriate. Viral loads will be serially quantified at each study time point to correlate changes in immune responses with the volume of circulating virus-infected cells. Tetrameric frequencies for population groups (e.g., early vs late/non-thymectomy) will be compared using Mann-Whitney U test, and between time-points for paired patient sample using Wilcoxon signed-rank test.

Patient and public involvement

The Young Person's Advisory Group North England (YPAGne) was involved in the development of the study design, patient facing documents (e.g., PIS) and the informed consent process. Ongoing consultation with YPAGne will continue to influence participant recruitment, outcome measure priorities and the acceptability of study methods.

Ethics

The ITHACA study has both research governance and ethical approvals (IRAS project ID: 298986; REC reference number: 21/NS/0142) and is adopted onto the National Institute for Health Research (NIHR) Clinical Research Network portfolio. Study organisation and sponsorship will be provided by The Newcastle upon Tyne Hospitals NHS Foundation Trust including coverage of insurance and NHS indemnity.

1
2
3 No significant risks are anticipated for enrolled participants. Study samples will be taken at
4 the same time as routine transplant investigations during clinic visits, thereby avoiding any
5 additional discomfort or hospital attendance. The estimated volume of study-related blood
6 samples required at each assessment time point is based on guidance from the World Health
7 Organisation (WHO) for trial-related blood volumes in children.^[15] This has been determined
8 to be safe without any risk of causing anaemia.
9
10
11
12
13
14
15

16 **Dissemination**

17
18 Study findings will be disseminated widely through publications in high impact peer-reviewed
19 journals, national and international conferences, and stakeholder events. We will engage
20 YPAGne to identify patient-centred forums to facilitate discussion of study progress and any
21 relevant findings with the general public. Published data will be made available via a public
22 data repository, with a digital object identifier included in any published manuscript to aid
23 discovery and outline access conditions. Potentially identifiable data, including patient sex,
24 date of birth and date of transplant will not be shared. Any unpublished data will only be
25 shared with other parties where a data access agreement has been negotiated by Newcastle
26 University Legal Services team on behalf of the study's chief investigator (CI).
27
28
29
30
31
32
33
34
35

36 **Acknowledgements**

37
38 The authors thank the study participants and their families. We acknowledge the significant
39 contribution of the YPAGne team in refining the ITHACA study design. We would also like to
40 thank Lesley Brindley (Clinical Trials Co-ordinator) and all of the transplant co-ordinators and
41 transplant nurse specialists for their assistance in the screening and recruitment of study
42 participants.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Mynarek M, Schober T, Behrends, U et al (2013). Posttransplant lymphoproliferative disease after pediatric solid organ transplant. *Clin Dev Immunol*; 814973.
2. Swerdlow SH, Campo E, Harris NL, et al. eds (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). Lyon: International Agency for Research on Cancer.
3. Offor UT, Bacon CM, Roberts, J et al (2021). Transplantation for congenital heart disease is associated with an increased risk of EBV-related posttransplant lymphoproliferative disorder in children. *J Heart Lung Transplant*; 40(1): 24 – 32.
4. Schober T, Framke T, Kreipe H et al (2013). Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. *Transplantation*; 95:240–246.
5. Minard-Colin V, Auperin A, Pillon M et al (2020). Rituximab for High-Risk Mature B-Cell Non-Hodgkin Lymphoma in Children. *N Engl J Med*; 382: 2207 – 2219.
6. Gross TG, Orjuela MA, Perkins SL et al (2012). Low-dose chemotherapy and Rituximab for posttransplant lymphoproliferative disease (PTLD): A Children’s Oncology Group Report. *Am J Transplant*; 12(11): 3069 – 3075.
7. Taj MM, Hadzic N, Height SE, et al (2012). Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004. *Leuk Lymphoma*; 53(5): 842-848.
8. Manlhiot C, Pollock-Barziv SM, Holmes C, et al (2010). Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. *J Heart Lung Transplant*; 29: 648 – 657.
9. Webber SA, Naftel DC, Fricker FJ, et al (2006). Lymphoproliferative disorders following pediatric heart transplantation. *Lancet*; 367: 233 – 239.
10. Marcellis L and Tousseyn (2019). The tumour microenvironment in post-transplant lymphoproliferative disorder. *Cancer Microenviron*;12(1):4–16
11. Ferla V, Rossi FG, Goldaniga MC et al (2020). Biological difference between Epstein–Barr virus positive and negative post-transplant lymphoproliferative disorders and their clinical impact. *Front Oncol*; 10: 506.

12. Ekman-Joelsson BM, Brandström P, Allén M et al (2022). Immunological differences between heart- and kidney-transplanted children: a cross-sectional study. *Cardiol Young*; 24: 1 – 6.
13. Yamada M, Macedo C, Louis K et al (2023). Distinct association between chronic EBV infection and T cell compartments from pediatric heart, kidney, and liver transplant recipients. *Am J Transplant*; In press. PMID: 37187296.
14. Deya-Martinez A, Flinn, AM, Gennery AR (2020). Neonatal thymectomy in children – accelerating the immunologic clock? *J Allergy Clin Immunol*; 146(2):236-243.
15. Howie, SRC (2011). Blood sample volumes in child health research: review of safe limits. *Bull World Health Organ*; 89(1): 46 – 53.
16. Park LM, Lannigan J, Jaimes MC (2020). OMIP-069: Forty-Color Full Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human Peripheral Blood. *Cytometry A*; 97(10): 1044 – 1051.
17. Xu Q, Milanez-Almeida P, Martins AJ, et al (2023). Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children. *Nature Immunol*; 24: 186–199.
18. Long HM, Chagoury OL, Leese AM, et al (2013). MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. *J Exp Med*; 210(5): 933–949.
19. Taylor GS, Long HM, Brooks JM, et al (2015). The immunology of Epstein-Barr virus-induced disease. *Annu Rev Immunol*; 33: 787 – 821.
20. Zuo J, Dowell AC, Pearce H, et al (2021). Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. *Nat Immunol*; 22(5): 620 – 626.
21. Long HM, Leese AM, Chagoury OL, et al (2011). Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. *J Immunol*; 187(1): 92-101.
22. Harris PA, Taylor R, Thielke R, et al (2009). Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*; 42: 377–81.
23. Harris PA, Taylor R, Minor BL, et al (2019). The REDCap Consortium: building an international community of software platform partners. *J Biomed Inform*; 95: 103208.
24. NHS England (2017). [Cardiothoracic Transplantation Service \(Paediatrics\)](#)

Funding

This study is funded by the Lymphoma Research Trust and Cancer Research UK (CRUK) [PHSTU-Hist\100297].

Contributors

UTO and SB conceptualised the study. UTO, SB, CMB, ARG and HML contributed to the study design. SB (CI) and co-applicants UTO, CMB and ARG developed the protocol with contributions from PH, MO, JS and ZR. UTO drafted and prepared the study protocol manuscript and received comments from the co-authors. All authors reviewed and approved the final version of the manuscript for publication.




Figure 1: ITHACA study flow chart. *OHT - Orthotopic Heart Transplant

Supplementary Table 1: Clinical data collected for the ITHACA Study. *Age at 1st median sternotomy is an agreed proxy where thymectomy isn't clearly documented in the patient's surgical notes.

Category	Clinical data
I. Baseline patient details	Age at transplant, Age at thymectomy*, Cardiothoracic procedure at time of thymectomy, Sex, Ethnicity, Weight, Height, Comorbidities prior to transplantation, Concomitant medication at time of transplantation.
II. Transplant-related	Cardiac/Renal diagnosis, Indication for transplant, Blood group compatibility.
III. Infection-related	EBV and CMV (where available) serostatus of donor & recipient at transplant.
IV. Immunosuppression	Induction therapy, maintenance immunosuppression drugs (dose and trough levels at each follow up visit), changes to maintenance immunosuppression drugs and indication for changes.
V. Complications	Opportunistic infections, Graft failure/rejection, PTLD, Mortality, documentation of "other" complications.
VI. Follow up	Weight, Height, Additional medication, Relevant additional comments (also see categories IV & V)

BMJ Open

The Immunology of Thymectomy And childhood Cardiac transplant (ITHACA): Protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-079582.R1
Article Type:	Protocol
Date Submitted by the Author:	04-Oct-2023
Complete List of Authors:	<p>Offor, Ugonna; Newcastle University Faculty of Medical Sciences, Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute.; Great North Children's Hospital, Department of Paediatric Haematology and Oncology</p> <p>Hollis, Paolo; Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Cardiothoracic Transplant</p> <p>Ognjanovic, Milos; Great North Children's Hospital, Department of Paediatric Nephrology</p> <p>Parry, Gareth; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Cardiopulmonary Transplantation</p> <p>Khushnood, Abbas; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Cardiopulmonary Transplantation</p> <p>Long, Heather; University of Birmingham, Institute of Immunology and Immunotherapy</p> <p>Gennery, Andrew; Newcastle University Faculty of Medical Sciences, Translational and Clinical Research Institute; Great North Children's Hospital, Department of Paediatric Immunology and Haematopoietic Stem Cell Transplantation</p> <p>Bacon, Chris; Newcastle University Faculty of Medical Sciences, Wolfson Childhood Cancer Research Centre, Translational Research and Clinical Research Institute.; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Cellular Pathology</p> <p>Simmonds, Jacob; Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Cardiothoracic Transplant</p> <p>Reinhardt, Zdenka; Newcastle Upon Tyne Hospitals NHS Foundation Trust, Department of Cardiopulmonary Transplantation</p> <p>Bomken, Simon; Newcastle University Faculty of Medical Sciences, Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute.; Great North Children's Hospital, Department of Paediatric Haematology and Oncology</p>
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Oncology, Immunology (including allergy), Infectious diseases
Keywords:	Paediatric transplant surgery < PAEDIATRIC SURGERY, Paediatric

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	oncology < ONCOLOGY, Lymphoma < ONCOLOGY, IMMUNOLOGY, Risk Factors, Observational Study

SCHOLARONE™
Manuscripts

1
2
3 **The Immunology of THymectomy And childhood CARDiac transplant (ITHACA): Protocol for**
4 **a UK-wide prospective observational cohort study to identify immunological risk factors of**
5 **post-transplant lymphoproliferative disease (PTLD) in thymectomised children.**
6
7

8 Ugonna T Offor^{1,2}; Paolo Hollis³; Milos Ognjanovic⁴; Gareth Parry⁵; Abbas Khushnood⁵;
9 Heather M Long⁶; Andrew R Gennery^{7,8}; Chris M Bacon^{1,9}; Jacob Simmonds³; Zdenka
10 Reinhardt⁵; Simon Bomken^{1,2}.
11
12
13

14 **Correspondence to Dr Ugonna T Offor:** ugo.offor@newcastle.ac.uk
15
16
17

18 ¹Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute,
19 Newcastle University, Newcastle upon Tyne, United Kingdom.
20

21 ²Department of Paediatric Haematology and Oncology, The Great North Children's Hospital,
22 Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
23

24 ³Department of Cardiothoracic Transplant, Great Ormond Street Hospital for Children NHS
25 Foundation Trust, London, United Kingdom.
26

27 ⁴Department of Paediatric Nephrology, Great North Children's Hospital, Newcastle upon Tyne
28 Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
29

30 ⁵Department of Cardiopulmonary Transplantation, Newcastle upon Tyne Hospitals NHS
31 Foundation Trust, Newcastle upon Tyne, United Kingdom.
32

33 ⁶Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
34

35 ⁷Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne,
36 United Kingdom.
37

38 ⁸Department of Paediatric Immunology and Haematopoietic Stem Cell Transplantation, The
39 Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust,
40 Newcastle upon Tyne, United Kingdom.
41

42 ⁹Department of Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust,
43 Newcastle upon Tyne, United Kingdom.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction:

Paediatric heart transplant patients are disproportionately affected by Epstein-Barr virus-related posttransplant lymphoproliferative disease (EBV-PTLD) compared to other childhood solid organ recipients. The drivers for this disparity remain poorly understood. A potential risk factor within this cohort is the routine surgical removal of the thymus – a gland critical for the normal development of T-lymphocyte mediated antiviral immunity – in early life, which does not occur in other solid organ transplant recipients. Our study aims to describe the key immunological differences associated with early thymectomy, its impact on the temporal immune response to EBV infection and subsequent risk of PTLD.

Methods and analysis:

Prospective and sequential immune monitoring will be performed for 34 heart transplant recipients and 6 renal transplant patients (aged 0-18 years), stratified into early (<1-year), late (>1-year) and non-thymectomy groups. Peripheral blood samples and clinical data will be taken before transplant and at 3-, 6-, 12- and 24-months post-transplant. Single cell analysis of circulating immune cells and enumeration of EBV-specific T-lymphocytes will be performed using high dimensional spectral flow cytometry with MHC I/II tetramer assay respectively. EBV antibodies and viral load will be monitored at each of the pre-defined study time points.

Ethics and dissemination:

Ethical approval for this study has been obtained from the North of Scotland Research Ethics Committee. The results will be disseminated through publications in peer-reviewed journals, presentations at scientific conferences and patient-centred forums, including social media.

Trial registration number: ISRCTN10096625

Strengths and limitations of this study

- This is the first prospective study to monitor the temporal immune response to EBV infection within a group of patients known to be at a high risk of developing PTLD.
- The integration of data from clinical parameters, in-depth immunophenotyping and EBV-specific T-lymphocyte functional assay permits robust analysis of potential predictive immune biomarkers.
- The multicentre study design optimises recruitment of participants.
- The primary study limitation is the low incidence of paediatric heart transplantation which may affect the rate of study recruitment.

Introduction

Post-Transplant Lymphoproliferative Disease (PTLD) is the most common childhood cancer in paediatric recipients of a solid organ transplant (SOT). This heterogeneous group of life-threatening lymphoid malignancies is typically driven by Epstein-Barr Virus (EBV) infection.[1] PTLD comprises a histological spectrum that ranges from indolent non-destructive B-cell lymphoid infiltrates through to more aggressive and destructive polyclonal or monoclonal B-cell lymphomas e.g., Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These destructive PTLD subtypes are indistinguishable from high grade mature B-cell lymphomas seen in immunocompetent children.[2] Their incidence is allograft-dependent and ranges from 1-2% in renal transplant recipients to as high as 10-15% in heart transplant patients.[1,3]

PTLD has one of the worst clinical outcomes amongst childhood lymphomas. The estimated 2-year Event-Free Survival (EFS) is 70% compared to 94% in sporadic cases within the general paediatric population.[4 – 6] In even starker contrast is the survival outcome for paediatric heart transplant patients, who ostensibly have an inferior EFS compared to other non-cardiac organ transplants.[7, 8] The reasons for this potential disparity are still poorly understood, albeit partly ascribed to a higher incidence of therapeutic complications from organ rejection and treatment-related toxicities.[9]

The pathogenesis of PTLD is complex and multifactorial. It involves the interplay between EBV-driven lymphoproliferation, iatrogenic immunosuppression and the suspected functional

1
2
3 exhaustion of T-lymphocytes due to graft-initiated chronic antigen stimulation.[10] The role of
4 EBV is clearly established in children, many of whom experience primary infection from an
5 EBV-mismatched organ.[1, 3, 4] In vitro and in vivo studies focused mainly on adult
6 monomorphic PTLD have demonstrated distinct patterns of viral protein expression in infected
7 B-lymphocytes.[10, 11] These expression patterns likely influence both the cellular
8 composition of the tumour immune microenvironment and aberrant immune signalling which
9 result in immune escape of tumour cells.[10]
10
11
12
13
14
15
16
17

18 In paediatric heart transplant patients, cardiac surgery via median sternotomy in early
19 childhood often requires routine thymectomy in order to access the heart and great vessels.
20 Our earlier study retrospectively examined risk factors for PTLD in the largest UK cohort of
21 paediatric orthotopic heart transplant (OHT) patients to date.[3] The risk of PTLD was found
22 to be significantly higher in children with congenital heart disease (CHD) [Hazard Ratio = 3.2;
23 95% CI = 1.4–7.4] and early thymectomy in infancy [Hazard Ratio = 2.7; 95% CI = 1.3–5.2].[3]
24 Furthermore, children with CHD had persistently lower T-lymphocyte counts compared to
25 children transplanted for acquired cardiomyopathy [CD4+: 430 cell/ μ l vs 963 cells/ μ l, $p < 0.01$
26 and CD8+: 367 cells/ μ l vs 765 cells/ μ l, $p < 0.01$].[3] Similar studies have identified marked
27 phenotypic and functional disruptions to the T-lymphocyte compartment in paediatric heart
28 transplant patients compared to children receiving a liver or kidney transplant. [12, 13]
29
30
31
32
33
34
35
36
37
38
39

40 During the first year of life, the thymus plays a crucial role in the development of cell-mediated
41 immunity, providing a microenvironment for precursor T-lymphocytes to proliferate and
42 differentiate into mature (naïve) T-lymphocytes.[14] Whilst it has been shown that neonatal
43 thymectomy alone is associated with premature immunosenescence and an increased risk of
44 viral infections such as Cytomegalovirus (CMV),[14] little is known about the immunological
45 consequences of early thymectomy in immunosuppressed transplant patients. In particular,
46 there are no data on the synergetic impact of thymectomy and transplant-related
47 immunosuppression on EBV-specific immunity and the subsequent risk of developing PTLD.
48
49
50
51
52
53
54
55
56
57
58
59
60

Study aims and hypothesis.

This study aims to investigate the development of EBV-specific immune responses following childhood heart transplant. Specifically, it aims to identify the impact of early thymectomy – compounded by iatrogenic immunosuppression – on EBV immunology and the risk of PTLD.

We hypothesise that a combination of early thymectomy and lifelong immunosuppression therapy establishes a tolerogenic immune profile consisting of dysregulated, exhausted and senescent immune cell subsets, poorly able to control EBV infection. This dysfunctional immune microenvironment permits the uncontrolled proliferation of EBV-infected B-lymphocytes and the subsequent development of PTLD.

Methods and analysis

Study design and setting

The Immunology of Thymectomy and Childhood Cardiac Transplant (ITHACA) study is a prospective nationwide cohort study recruiting children (0-18 years) from the two UK centres currently commissioned to provide paediatric heart transplant services: The Freeman Hospital, Newcastle upon Tyne and Great Ormond Street Hospital for Children, London. The study cohort will consist of 34 prospective heart transplant recipients and a non-thymectomy age-matched control group made up of 6 renal transplant recipients. All patients meeting the study's eligibility criteria will be identified and recruited through their local transplant teams at the time of listing for cardiac or renal transplantation. The study opened to patient recruitment in March 2022 and is expected to recruit until June 2024.

Inclusion Criteria

- Aged 0 – 18 years.
- Actively listed on the NHS Blood and Transplant (NHSBT) waiting list for a primary organ transplant OR awaiting transplant with a living related donor kidney OR recently transplanted with pre-transplant blood samples available.
- Written informed consent.

Exclusion Criteria

- Has a pre-existing diagnosis of an inherited or acquired immunodeficiency.
- Has an underlying thymic disorder.
- Has previously received a bone marrow or organ transplant.
- Has had a previous cancer diagnosis.
- Withheld consent.
- Weight under 2.5kg.

Informed consent

Informed consent will be obtained from the parent/carer of the eligible child or from the patient themselves if over the age of 16 years. Assent may be given by children < 16 years of age who wish to do so.

A deferred consent approach will be employed for potential study participants who attend a research site's transplant service for transplantation in a critical/life threatening clinical situation. This will involve the collection of baseline study samples from potential participants at the point of pre-surgical workup without written informed consent being received. Discussion about the study, the giving of participant information sheet (PIS) and receiving of written informed consent/assent will be offered at a more appropriate time before further follow-up blood tests are taken. Such cases will require that the clinical team considers obtaining informed consent prior to transplant to be inappropriate. This will be documented in the patient's clinical notes. Study samples collected under such circumstances will be processed for storage but not analysed until written informed consent is obtained. Any patient who has study samples collected by deferred consent but subsequently declines enrolment in the study will have their samples destroyed in a timely manner according to local laboratory standard operating procedures (SOP). Additional consent will be sought to store specimens for future ethically approved research.

Assessment and procedures

Children will undergo blood sampling for study-specific investigations during routine clinical visits prior to transplant and at 3-, 6-, 12- and 24-months post-transplant (Figure 1). No additional study-related hospital visits are planned. Medical therapy will be applied as clinically indicated and per the local post-transplantation protocols. A total of 5 – 20mls of blood will be taken at each study time point for all participants. This will coincide with their usual transplant-related investigations in adherence to WHO guidance for blood sampling in child health research.[15] In the case of a prolonged interval between the pre-transplant blood sample and subsequent organ transplant (e.g., > 6 months) additional blood samples will be specifically requested from the patient/parent and verbal consent recorded in the medical record. Relevant clinical data will also be collected from participants at each study time point (Supplementary Table 1).

Study investigations will consist of:

- Immunophenotyping of circulating immune cell subsets.
- EBV serology.
- EBV-specific T-lymphocyte quantification.
- EBV-specific T-lymphocyte functional analysis.

Immunophenotyping of circulating immune cell subsets

Circulating immune cell populations will be analysed in Newcastle University laboratories. Mononuclear cells (MNCs) will be isolated and cryopreserved from blood samples taken at each study time point. In addition, biobanked MNC samples from age-matched healthy children will be included for analysis as non-thymectomy, non-transplant controls. Circulating immune cell subsets will be identified within samples using high dimensional spectral flow cytometry (Aurora system [Cytex]). The 5-laser Aurora spectral cytometer enables an in-depth analysis of up to 40 cell surface markers at a time.[16] This is highly valuable in phenotypically characterising various immune cell populations and their subsets (including T-lymphocytes, B-lymphocytes, NK cells and dendritic cells) in low volume paediatric samples.[17] These

1
2
3 samples will be analysed simultaneously in batches to mitigate inter-assay variation. A
4 comprehensive list of cell surface markers has been selected to comprise the following:
5
6

- 7 (i) Major innate/adaptive cell lineages.
8
9 (ii) Main T-lymphocyte subsets as well as putative T-helper subsets.
10
11 (iii) Recent thymic activity.
12
13 (iv) Cellular exhaustion and senescence.
14
15 (v) Key innate/adaptive cells involved in immune response to EBV infection.
16
17

18 Two full spectrum flow panels have been validated for this purpose. A 24-colour panel has
19 been designed to probe the wider circulating immune landscape of the study cohort (Table
20 1). This is complemented by a targeted 30-colour T-lymphocyte panel that will elucidate any
21 temporal changes in the T-lymphocyte compartment after transplantation (Table 2).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Cell surface markers of interest used in the Broad immune full spectrum flow for the ITHACA study.

Cell surface marker	Fluorophore	Antibody clone	Purpose
CD45	Spark YG 593	HI03	Leucocytes
TCRγd	PerCP-eFluor 710	B1.1	γ d T-lymphocyte
CD3	BV 510	SK7	Pan T cell, NK T-like cells
CD4	PerCP	SK3	CD4 T helper lymphocytes
CD8	BUV 805	SK1	CD8 cytotoxic T-lymphocytes
CD11c	PE-Cy7	B-ly6	Dendritic cell differentiation
CD14	Spark Blue 550	63D3	Monocyte differentiation
CD16	BUV 496	3G8	Monocyte, NK cell, and Dendritic cell differentiation
CD19	Spark NIR 685	HIB19	B lymphocytes
CD20	BV 786	2H7	B lymphocytes
CD21	PE-Cy5	B-ly4	B lymphocyte differentiation
CD24	PE-AF 610	SN3	B lymphocyte differentiation
CD27	APC-H7	M-T271	T/B lymphocyte differentiation
CD38	APC-Fire 810	HIT2	Monocyte, Dendritic cell, T/B lymphocyte activation and differentiation
CD56	BUV 737	NCAM16.2	NK cells
CD57	Pacific Blue	NK-1	NK and CD8 T lymphocyte immune senescence
CD123	Super Bright 436	6H6	Plasmacytoid dendritic cells
CD127	APC-R700	HIL-7R-M21	Cytokine receptor; T lymphocyte differentiation
KIR (CD158)	BUV 605	DX27	NK cells
NKG2A (CD159a)	APC	REA110	NK cells
NKG2C (CD159c)	PE	REA205	NK cells
IgD	BV 480	IA6-2	B lymphocyte differentiation
IgM	BV 570	MHM-88	B lymphocyte differentiation
HLA-DR	PE-Fire 810	L243	Monocyte activation, dendritic cell lineage, NK cell lineage discrimination,
Viability	Live/Dead Blue	-	Live cells

Table 2: Cell surface markers of interest used in the T lymphocyte full spectrum flow panel for the ITHACA study.

Cell surface marker	Fluorophore	Antibody clone	Purpose
CD45	Spark YG 593	HI03	Leucocytes
CD45RA	BUV 395	5H9	T lymphocyte differentiation
CD3	BV510	SK7	Pan T cell, NK T-like cells
CD4	PerCP	SK3	CD4 T helper lymphocytes
CD8	BUV 805	SK1	CD8 cytotoxic T lymphocytes
TCRγd	PerCP-eFluor 710	B1.1	γ d T lymphocyte
CD25	PE-AF700	CD25-3G10	Regulatory T lymphocytes
CD27	APC-H7	M-T271	T lymphocyte differentiation
CD28	BV650	CD28.2	T lymphocyte differentiation
CD31	BV711	WM59	Recent thymic emigrants
CD38	APC-Fire 810	HIT2	T lymphocyte activation/differentiation
CD39	BUV 661	TU66	Regulatory T lymphocytes
CD57	Pacific Blue	NK-1	CD8 T lymphocyte immune senescence
CD62L	BUV 496	SK-11	T lymphocyte differentiation
CD69	AF 647	FN50	T lymphocyte activation
CD95	PE-Cy5	DX2	T lymphocyte activation/differentiation
CD127	APC-R700	HIL-7R-M21	Chemokine receptor; T lymphocyte differentiation
HLA-DR	PE-Fire 810	L243	T lymphocyte activation
CCR4	BB 700	1G1	Chemokine receptor; T lymphocyte differentiation
CCR5	BUV 563	2D7/CCR5	Chemokine receptor; T lymphocyte differentiation
CCR6	BV 480	140706	Chemokine receptor; T lymphocyte differentiation
CCR7	BV 421	G043H7	T lymphocyte differentiation
CXCR3	AF 488	GH025H7	Chemokine receptor; T lymphocyte differentiation
CXCR5	BV 750	RF8B2	Chemokine receptor; T lymphocyte differentiation
PD-1	BV 785	EH12.2H7	Co-inhibitory receptor; T lymphocyte exhaustion
LAG-3	PE-Cy7	3DS223H	Co-inhibitory receptor; T lymphocyte exhaustion
TIM-3	BV 605	F38-2E2	Co-inhibitory receptor; T lymphocyte exhaustion
CTLA4	PE-CF594	BNI3	Co-inhibitory receptor; T lymphocyte exhaustion
Tetramer (lytic)	APC	-	EBV-specific T lymphocytes
Tetramer (latent)	PE	-	EBV-specific T lymphocytes
Viability	Live/Dead Blue	-	Live cells

EBV serology

Routine blood samples for evaluation of EBV serology will be tested centrally in the Newcastle upon Tyne NHS Hospitals Foundation Trust (NUTH) virology laboratories. EBV and CMV viral load will be measured from whole blood using polymerase chain reaction (PCR) assays. Serum and/or plasma will be tested for antibody response to key EBV proteins including IgM/IgG for Viral Capsid Antigen (VCA) and IgG for EBV Nuclear Antigen 1 (EBNA-1). Results for viral load assay will be reported as total titres while antibody testing will be reported as a binary detected/not detected based on NUTH laboratories reference cut-off values.

EBV-specific T-lymphocyte quantification

An optimised panel of HLA-restricted peptide-MHC (pMHC) I/II tetramers will be used to evaluate EBV-specific CD8 and CD4 T-lymphocyte immunity at the time points outlined in Figure 1.[18] This panel will be tailored to maximise coverage of participants who have the most commonly expressed HLA genotypes within our study cohort. Combinations of differently fluorescently labelled pMHC tetramers presenting purified peptides of dominant lytic and latent EBV epitopes,[19] relevant for the patient HLA genotype, will be included in the T-lymphocyte panel where applicable (Table 2). These customised tetramers will be procured from the National Institute of Health (NIH) Tetramer Core Facility, Atlanta, Georgia, USA.

EBV-specific T-lymphocyte functional analysis

To assess the functional capacity of EBV-specific T-lymphocytes in an HLA-unbiased manner, effector cytokine production of interferon gamma (IFN- γ) will be determined by ELISpot following stimulation with pools of overlapping peptides (JPT PepMix™) representing the full sequences of a panel of EBV latent and lytic cycle proteins.[20, 21]

Data collection

Study data will be collated and managed using Research Electronic Data Capture (REDCap) electronic case report forms (eCRF). [22] REDCap is a secure, web-based platform specifically designed to support data acquisition for research studies. It provides restricted user rights to

1
2
3 protect identifiable data, including audit trails for tracking data handling and export and
4 procedures for data integration with external sources. [23]
5
6
7
8

9 Outcome Measures

10 Primary Outcomes Measures:

- 11 1) Proportions of circulating innate and adaptive immune cell subsets before and at 3-, 6-,
12 12- and 24-months post-transplant.
- 13 2) Frequency of detectable EBV-specific T-lymphocyte immunity.
- 14 3) Functional capacity of EBV-specific T-lymphocytes.

15
16
17
18
19
20
21 Secondary Outcome Measures:

- 22 1) Incidence of EBV infection.
- 23 2) Time from transplantation to EBV viraemia.
- 24 3) Time from EBV viraemia to seroconversion.

25 Data analysis plan

26 Sample size calculation

27
28
29
30
31
32
33
34 As the study objectives are largely descriptive, no sample size calculation is necessary. Instead,
35 we selected our sample size such that the study is feasible and large enough to conduct
36 comprehensive analyses. Therefore, our sample size is based on a national average of 30
37 childhood cardiac transplants per year, [24] and a 60% recruitment rate. All eligible patients
38 listed on the National Health Service Blood and Transplant (NHSBT) register will be
39 approached for consent, recognising that not all of these patients will receive a transplant
40 during the lifetime of this study. However, any pre-transplant blood samples that have been
41 obtained are equally important to achieve the study's primary outcome measure.
42
43
44
45
46
47
48
49

50 Statistical analysis

51
52
53 Data from spectral flow cytometry will be analysed using the OMIQ platform
54 (<https://www.omiq.ai/>). Automated clustering and dimensionality reduction will be used to
55 identify immune cell populations by FlowSOM and Uniform Manifold Approximation and
56 Projection (UMAP) respectively. These techniques overcome the practical challenges
57 associated with manual gating and user bias when analysing datasets from large flow panels.
58
59
60

1
2
3 Statistically different immune signatures between patients with early thymectomy and late or
4 non-thymectomy, EBV+ and EBV- serostatus, and between time-points, will be identified by
5 linear and generalised linear mixed models (statistical significance defined as $p < 0.05$).
6
7 Continuous variables will be assessed by Pearson correlation using the single linkage method
8
9 to group patients by expression values, and non-continuous variables by non-parametric
10
11 Spearman correlation, as appropriate. Viral loads will be serially quantified at each study time
12
13 point to correlate changes in immune responses with the volume of circulating virus-infected
14
15 cells. Tetrameric frequencies for population groups (e.g., early vs late/non-thymectomy) will
16
17 be compared using Mann-Whitney U test, and between time-points for paired patient sample
18
19 using Wilcoxon signed-rank test.
20
21
22

23 Patient and public involvement

24
25 The Young Person's Advisory Group North England (YPAGne) was involved in the development
26
27 of the study design, patient facing documents (e.g., PIS) and the informed consent process.
28
29 Ongoing consultation with YPAGne will continue to influence participant recruitment,
30
31 outcome measure priorities and the acceptability of study methods.
32
33

34 Ethics

35
36 The ITHACA study has both research governance and ethical approvals (IRAS project ID:
37
38 298986; REC reference number: 21/NS/0142) and is adopted onto the National Institute for
39
40 Health Research (NIHR) Clinical Research Network portfolio. Study organisation and
41
42 sponsorship will be provided by The Newcastle upon Tyne Hospitals NHS Foundation Trust
43
44 including coverage of insurance and NHS indemnity.
45
46

47
48 No significant risks are anticipated for enrolled participants. Study samples will be taken at
49
50 the same time as routine transplant investigations during clinic visits, thereby avoiding any
51
52 additional discomfort or hospital attendance. The estimated volume of study-related blood
53
54 samples required at each assessment time point is based on guidance from the World Health
55
56 Organisation (WHO) for trial-related blood volumes in children. [15] This has been determined
57
58 to be safe without any risk of causing anaemia.
59
60

Dissemination

Study findings will be disseminated widely through publications in high impact peer-reviewed journals, national and international conferences, and stakeholder events. We will engage YPAGne to identify patient-centred forums to facilitate discussion of study progress and any relevant findings with the general public. Published data will be made available via a public data repository, with a digital object identifier included in any published manuscript to aid discovery and outline access conditions. Potentially identifiable data, including patient sex, date of birth and date of transplant will not be shared. Any unpublished data will only be shared with other parties where a data access agreement has been negotiated by Newcastle University Legal Services team on behalf of the study's chief investigator (CI).

Acknowledgements

The authors thank the study participants and their families. We acknowledge the significant contribution of the YPAGne team in refining the ITHACA study design. We would also like to thank Lesley Brindley (Clinical Trials Co-ordinator) and all of the transplant co-ordinators and transplant nurse specialists for their assistance in the screening and recruitment of study participants.

References

1. Mynarek M, Schober T, Behrends, U et al (2013). Posttransplant lymphoproliferative disease after pediatric solid organ transplant. *Clin Dev Immunol*; 814973.
2. Swerdlow SH, Campo E, Harris NL, et al. eds (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). Lyon: International Agency for Research on Cancer.
3. Offor UT, Bacon CM, Roberts, J et al (2021). Transplantation for congenital heart disease is associated with an increased risk of EBV-related posttransplant lymphoproliferative disorder in children. *J Heart Lung Transplant*; 40(1): 24 – 32.
4. Schober T, Framke T, Kreipe H et al (2013). Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. *Transplantation*; 95:240–246.
5. Minard-Colin V, Auperin A, Pillon M et al (2020). Rituximab for High-Risk Mature B-Cell Non-Hodgkin Lymphoma in Children. *N Engl J Med*; 382: 2207 – 2219.

- 1
2
3 6. Gross TG, Orjuela MA, Perkins SL et al (2012). Low-dose chemotherapy and Rituximab
4 for posttransplant lymphoproliferative disease (PTLD): A Children's Oncology Group
5 Report. *Am J Transplant*; 12(11): 3069 – 3075.
- 6
7
8
9 7. Taj MM, Hadzic N, Height SE, et al (2012). Long-term outcome for immune suppression
10 and immune related lymphoproliferative disorder: prospective data from the United
11 Kingdom Children's Leukaemia and Cancer Group registry 1994-2004. *Leuk*
12 *Lymphoma*; 53(5): 842-848.
- 13
14
15
16 8. Manlhiot C, Pollock-Barziv SM, Holmes C, et al (2010). Post-transplant
17 lymphoproliferative disorder in pediatric heart transplant recipients. *J Heart Lung*
18 *Transplant*; 29: 648 – 657.
- 19
20
21
22 9. Webber SA, Naftel DC, Fricker FJ, et al (2006). Lymphoproliferative disorders following
23 pediatric heart transplantation. *Lancet*; 367: 233 – 239.
- 24
25
26
27 10. Marcellis L and Tousseyn (2019). The tumour microenvironment in post-transplant
28 lymphoproliferative disorder. *Cancer Microenviron*;12(1):4–16
- 29
30
31
32 11. Ferla V, Rossi FG, Goldaniga MC et al (2020). Biological difference between Epstein–
33 Barr virus positive and negative post-transplant lymphoproliferative disorders and
34 their clinical impact. *Front Oncol*; 10: 506.
- 35
36
37
38 12. Ekman-Joelsson BM, Brandström P, Allén M et al (2022). Immunological differences
39 between heart- and kidney-transplanted children: a cross-sectional study. *Cardiol*
40 *Young*; 24: 1 – 6.
- 41
42
43
44 13. Yamada M, Macedo C, Louis K et al (2023). Distinct association between chronic EBV
45 infection and T cell compartments from pediatric heart, kidney, and liver transplant
46 recipients. *Am J Transplant*; In press. PMID: 37187296.
- 47
48
49
50 14. Deya-Martinez A, Flinn, AM, Gennery AR (2020). Neonatal thymectomy in children –
51 accelerating the immunologic clock? *J Allergy Clin Immunol*; 146(2):236-243.
- 52
53
54
55 15. Howie, SRC (2011). Blood sample volumes in child health research: review of safe
56 limits. *Bull World Health Organ*; 89(1): 46 – 53.
- 57
58
59
60 16. Park LM, Lannigan J, Jaimes MC (2020). OMIP-069: Forty-Color Full Spectrum Flow
Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human
Peripheral Blood. *Cytometry A*; 97(10): 1044 – 1051.

17. Xu Q, Milanez-Almeida P, Martins AJ, et al (2023). Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children. *Nature Immunol*; 24: 186–199.
18. Long HM, Chagoury OL, Leese AM, et al (2013). MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response. *J Exp Med*; 210(5): 933–949.
19. Taylor GS, Long HM, Brooks JM, et al (2015). The immunology of Epstein-Barr virus-induced disease. *Annu Rev Immunol*; 33: 787 – 821.
20. Zuo J, Dowell AC, Pearce H, et al (2021). Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. *Nat Immunol*; 22(5): 620 – 626.
21. Long HM, Leese AM, Chagoury OL, et al (2011). Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. *J Immunol*; 187(1): 92-101.
22. Harris PA, Taylor R, Thielke R, et al (2009). Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*; 42: 377–81.
23. Harris PA, Taylor R, Minor BL, et al (2019). The REDCap Consortium: building an international community of software platform partners. *J Biomed Inform*; 95: 103208.
24. NHS England (2017). [Cardiothoracic Transplantation Service \(Paediatrics\)](#)

Funding

This study is funded by the Lymphoma Research Trust (N/A) and Cancer Research UK (CRUK) [PHSTU-Hist\100297]. SB is funded by an MRC Clinician Scientist Fellowship (MR/S021590/1).


Contributors

UTO and SB conceptualised the study. UTO, SB, CMB, ARG and HML contributed to the study design. SB (CI) and co-applicants UTO, CMB and ARG developed the protocol with contributions from PH, MO, GP, AK, JS and ZR. UTO drafted and prepared the study protocol manuscript and received comments from the co-authors. All authors reviewed and approved the final version of the manuscript for publication.

1
2
3 **Figure Legend/Caption:**
4

5 Figure 1: ITHACA study flow chart. *OHT: Orthotopic Heart Transplant
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



Supplementary Table 1: Clinical data collected for the ITHACA Study. *Age at first median sternotomy is an agreed proxy where thymectomy isn't clearly documented in the patient's surgical notes.

Category	Clinical data
Baseline patient details	Age at transplant, Age at thymectomy*, Type of thymectomy (Total vs Partial), Type and date of first cardiac surgery (if not transplant), Cardiothoracic procedure at time of thymectomy, Sex, Ethnicity, Weight, Height, Comorbidities prior to transplantation, Concomitant medication at time of transplantation.
Transplant-related	Cardiac/Renal diagnosis, Indication for transplant, Blood group compatibility.
Infection-related	EBV and CMV (where available) serostatus of donor & recipient at transplant.
Immunosuppression	Induction therapy, maintenance immunosuppression drugs (dose and trough levels at each follow up visit), changes to maintenance immunosuppression drugs and indication for changes.
Complications	Opportunistic infections, Graft failure/rejection, PTLD, Mortality, documentation of "other" complications.
Follow up	Weight, Height, Additional medication, Relevant additional comments (also see categories IV & V)